GlassScriptPhysician profile
Bryan Velasco
NPI 1316640253
$724.15
in general payments reported to CMS, 2019-2025
17 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $389 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $107.52 | 2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $97.07 | 2024-2025 | Ultomiris |
| Amgen INC. | $85.53 | 2024-2025 | Uplizna |
| Abbvie INC. | $70.00 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $59.63 | 2024-2025 | |
| Sk Life Science, INC. | $45.89 | 2024-2025 | |
| Neurelis, INC. | $32.94 | 2024-2025 | Valtoco |
| Ucb, INC. | $32.26 | 2025 | Fintepla |
| Biogen, INC. | $27.40 | 2025 | Skyclarys |
| Blue Surgical LLC | $26.83 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $24.61 | 2025 | |
| Merz Pharmaceuticals, LLC | $22.15 | 2024 | Inbrija, Xeomin |
| Otsuka America Pharmaceutical, INC. | $19.26 | 2024 | Nuedexta |
| Pfizer INC. | $19.06 | 2024 | |
| Genentech USA, INC. | $18.80 | 2024 | Ocrevus Zunovo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $18.75 | 2024 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $16.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Velasco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.